Impact of Patient Involvement in Alerts Management of Telemonitoring CPAP
Adherence to CPAP determines the expected benefits of the treatment. A dose-benefit relationship has been demonstrated for both functional and cardiovascular benefits. The first few days' use of the device are decisive in determining long-term compliance. In this context, daily monitoring of the data teletransmitted me
| Condition(s) | OSA |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Adherence to CPAP determines the expected benefits of the treatment. A dose-benefit relationship has been demonstrated for both functional and cardiovascular benefits. The first few days' use of the device are decisive in determining long-term compliance. In this context, daily monitoring of the data teletransmitted means that we can be more responsive to problems of compliance during the first few days of use; the contribution of telemonitoring can be very positive in a context of poor compliance. In France, compulsory health insurance coverage of CPAP treatment is authorised for patients aged over 16 with clinical symptoms and an AHI ≥15 events per hour and \<30 events/h in patients with severe cardiovascular co-morbidity. These patients are often not very sleepy due to sympathetic hyper |
| Who can participate | Inclusion Criteria: * Adult with newly diagnosed OSA (with central apnea index \<5 ev/h), justifying CPAP and with low sleepiness (Epworth score \<11 at inclusion). * Patient with at least 1 cardiovascular risk factor (obesity, type I or II diabetes with or without treatment, permanent hypertension with or without treatment, heart failure with preserved ejection fraction, valve disease, history of atrial fibrillation, history of ischaemic heart disease, history of stroke). * Patient with a smartphone and who agrees to use connected objects during the study. * Signed informed consent form, * Subject affiliated to a health insurance system, or is a beneficiary. Exclusion Criteria: * Patients already fitted with a CPAP machine, * Patients with permanent atrial fibrillation, * Patients whose s |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Asten Sante |
| Locations | La Roche-sur-Yon, France, France; Paris, France, France; Angers, France; Dijon, France; Le Chesnay, France; Le Mans, France (+5 more sites) |
| Start date | 2023-09-29 |
| NCT ID | NCT05960175 |
| Official listing | https://clinicaltrials.gov/study/NCT05960175 |